RG1068 (synthetic human secretin)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatitis
Conditions
Pancreatitis
Trial Timeline
Mar 1, 2008 → Oct 1, 2009
NCT ID
NCT00660335About RG1068 (synthetic human secretin)
RG1068 (synthetic human secretin) is a phase 3 stage product being developed by Repligen for Pancreatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00660335. Target conditions include Pancreatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00660335 | Phase 3 | Completed |
| NCT00216294 | Phase 2 | Completed |
| NCT00036231 | Phase 3 | Terminated |
| NCT00036244 | Phase 3 | Completed |
Competing Products
8 competing products in Pancreatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CREON | AbbVie | Pre-clinical | 23 |
| Creon36™ | AbbVie | Phase 2 | 52 |
| Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium | AstraZeneca | Phase 1 | 33 |
| Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab | Merck | Phase 2 | 52 |
| aprepitant + Placebo | Merck | Pre-clinical | 23 |
| Meropenem | Pfizer | Approved | 84 |
| meropenem | Pfizer | Approved | 84 |
| Tanezumab | Pfizer | Phase 2 | 51 |